AbbVie Inc. Shares Surge Past Analyst Target: What’s Next?

In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $202.46, changing hands for $203.87/share. Investors now face a crucial decision: should analysts downgrade based on valuation, or adjust their targets higher? This decision often reflects recent business developments which may have influenced the stock’s upward trend.

AbbVie has 24 different analyst targets within the Zacks coverage universe contributing to the average. While some analysts hold lower expectations, with one setting a price target of $170.00, others anticipate much higher outcomes, with one target reaching $225.00. The standard deviation among these targets is $14.506, showcasing a wide range of opinions among analysts.

Examining the average ABBV price target can help investors gauge collective market sentiment. With ABBV now trading above the $202.46 average target price, it’s a pivotal moment for investors. They must weigh whether this price is simply a milestone towards greater gains or if it signals that the stock has reached a valuation peak, prompting considerations for profit-taking. Below is a table summarizing the current findings of analysts covering AbbVie Inc:

The average rating in the table is on a scale from 1 to 5, where 1 means Strong Buy and 5 is Strong Sell. This report utilizes data sourced from Zacks Investment Research via Quandl.com. Get the latest Zacks research report on ABBV — FREE.

The Top 25 Broker Analyst Picks of the S&P 500 »

Also see:

– IPOs
– ARA Price Target
– CNDA shares outstanding history

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.